Pharmacological Treatment of Acute Coronary Syndromes, 2014 Current Cardiovascular Therapy Series

Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs. The emphasis is on current practice, but with an eye to the near-future direction of treatment. This book is intended to update clinicians on recent data on the medical management of patients with Acute Coronary Syndromes. Alongside each book in the series, this title has been established to allow rapid publication of new editions to cover developments in the field.

Foreword.- Preface.- Anti-ischemic Therapy.- Antiaggregant Therapy: New potent P2Y12 inhibitors.- Anticoagulation Therapy: Heparins and Factor Xa inhibitors.- Secondary prevention in ACS The role of novel oral anticoagulants.- American vs European guidelines.- Critical appraisal.- Triple therapy: Risky but sometimes necessary.- Management of bleeding complications.

Pablo Avanzas, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain, and Peter Clemmensen, Department of Surgery and Internal Medicine, University of Copenhagen, Denmark.

Presents highly practical information on conventional and newer treatment options for ACS Emphasis is on a just-the-facts clinical approach to the pharmalogic treatment of ACS Discusses recommendations for antiplatelet and anticoagulant agents in the treatment of ACS patients